RedHill Biopharma (NASDAQ: RDHL) director details RSUs and stock options

Rhea-AI Filing Summary

RedHill Biopharma Ltd. director Reed Kenneth filed an initial ownership report showing equity interests in the company. He holds 10,520 unvested restricted share units, each tied to one American Depositary Share and settled in ordinary shares, plus 2,583 ADSs that are convertible at any time and have no expiration date.

He also holds stock options to purchase 90,000 ordinary shares (equivalent to 9 ADSs) at an exercise price of $4,870 per ADS expiring on March 25, 2030, 150,000 ordinary shares (equivalent to 15 ADSs) at $7,000 per ADS expiring on May 6, 2029, and 250,000 ordinary shares (equivalent to 25 ADSs) at $6,620 per ADS expiring on July 25, 2031. These options are fully vested and exercisable.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Reed Kenneth

(Last) (First) (Middle)

21 HA'ARBA'A STREET

(Street)

TEL AVIV 6473921

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	105,200,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(2)	(2)	Ordinary Shares	25,830,000	(2)	D
Stock Option (Right to Buy)	(3)	(3)	Ordinary Shares	90,000	(3)	D
Stock Option (Right to Buy)	(4)	(4)	Ordinary Shares	150,000	(4)	D
Stock Option (Right to Buy)	(5)	(5)	Ordinary Shares	250,000	(5)	D

Explanation of Responses:

1. Represents 10,520 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.

2. Represents 2,583 ADSs, which are convertible at any time, at the holder's election and have no expiration date.

3. Represents stock option to purchase 90,000 Ordinary Shares (equivalent to 9 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.

4. Represents stock option to purchase 150,000 Ordinary Shares (equivalent to 15 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,000 per ADS and the option expires on May 6, 2029.

5. Represents stock option to purchase 250,000 Ordinary Shares (equivalent to 25 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $6,620 per ADS and the option expires on July 25, 2031.

	/s/ Kenneth Reed	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the RedHill Biopharma (RDHL) Form 3 filing for Reed Kenneth show?

The Form 3 shows director Reed Kenneth’s initial equity holdings in RedHill Biopharma, including unvested RSUs, American Depositary Shares, and several fully vested stock options. It outlines his current ownership but does not report any recent buy or sell transactions.

How many unvested RSUs tied to ADSs does Reed Kenneth hold in RDHL?

Reed Kenneth holds 10,520 unvested restricted share units, each linked to one American Depositary Share of RedHill Biopharma. These RSUs are subject to time-based vesting conditions and are settled in the company’s ordinary shares once vesting requirements are met.

What American Depositary Share (ADS) position is reported for Reed Kenneth at RedHill Biopharma (RDHL)?

The filing reports that Reed Kenneth holds 2,583 American Depositary Shares of RedHill Biopharma. These ADSs are convertible at any time at the holder’s election and have no expiration date, providing ongoing exposure to the company’s ordinary shares.

What stock options does Reed Kenneth hold in RedHill Biopharma and when do they expire?

He holds options for 90,000 ordinary shares expiring March 25, 2030, 150,000 ordinary shares expiring May 6, 2029, and 250,000 ordinary shares expiring July 25, 2031. All these options are fully vested and exercisable under the RedHill 2010 Option Plan.

What are the exercise prices of Reed Kenneth’s RedHill Biopharma (RDHL) stock options?

The options have exercise prices of $4,870 per ADS for 90,000 ordinary shares, $7,000 per ADS for 150,000 ordinary shares, and $6,620 per ADS for 250,000 ordinary shares. Each option is fully vested and can be exercised before its stated expiration date.

Are Reed Kenneth’s stock options in RedHill Biopharma (RDHL) already vested?

Yes. The Form 3 footnotes state that the stock options to purchase 90,000, 150,000, and 250,000 ordinary shares are fully vested and exercisable. This means he can choose to exercise these options at their respective exercise prices before they expire.